Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Short-term Investments: 2018-2025

  • China SXT Pharmaceuticals' Short-term Investments was N/A to $31,001 in Q3 2025 from the same period last year, while for Sep 2025 it was $31,001, marking a year-over-year change of. This contributed to the annual value of $30,413 for FY2025, which is 344.50% up from last year.
  • China SXT Pharmaceuticals' Short-term Investments amounted to $31,001 in Q3 2025, which was up 1.93% from $30,413 recorded in Q1 2025.
  • Over the past 5 years, China SXT Pharmaceuticals' Short-term Investments peaked at $45,297 during Q1 2022, and registered a low of $6,842 during Q1 2024.
  • For the 2-year period, China SXT Pharmaceuticals' Short-term Investments averaged around $22,752, with its median value being $30,413 (2025).
  • Data for China SXT Pharmaceuticals' Short-term Investments shows a peak YoY surged of 344.50% (in 2025) over the last 5 years.
  • Over the past 4 years, China SXT Pharmaceuticals' Short-term Investments (Quarterly) stood at $25,947 in 2021, then spiked by 74.58% to $45,297 in 2022, then reached $6,842 in 2024, then surged by 344.50% to $31,001 in 2025.
  • Its Short-term Investments stands at $31,001 for Q3 2025, versus $30,413 for Q1 2025 and $6,842 for Q1 2024.